JWJohn Malcolm Walker

John Malcolm Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Malcolm Walker has a total of 376 co-authors. Here are the top co-authors by number of shared publications:

  • Dudley John Pennell

    National Heart and Lung Institute, Imperial College London

    23 shared publications
  • Derek Miles Yellon

    The Hatter Cardiovascular Institute, University College London

    13 shared publications
  • John B. Porter

    University College London, London, UK

    13 shared publications
  • Beatrix Wonke

    Department of Haematology, The Whittington Hospital, London, UK

    6 shared publications
  • Emma Prescott

    5 shared publications
  • Lisa J. Anderson

    From the Royal Brompton and Harefield National Health Service Foundation Trust, London, UK (J.-P.C., T.H., P.K., S.V.N., M.N.S., D.N.F., D.J.P.); National Heart and Lung Institute, Imperial College London, London, UK (J.-P.C., T.H., P.K., D.N.F., D.J.P.); St. George's Hospital National Health Service Trust, London, UK (L.J.A.); University College Hospitals National Health Service Trust, London, UK (M.R., J.B.P., J.M.W.); Children's Hospital Los Angeles, CA (J.C.W.); Università degli Studi di...

    5 shared publications

Latest Publications

  • Healthy bone marrow transplantation into hypertriglyceridemic rats improves cardiac reparative fibrosis post-myocardial infarction

    by Lisaidy Ramos-Regalado, Sebastià Alcover, Teresa Padró, Malcolm Walker, Guillermo Gómez de Segura-Melcón, Gemma Sancho-Pardo, Lina Badimon, Gemma Arderiu, Josep Balart, Gemma Vilahur

    Aims: Acute myocardial infarction (AMI) triggers an immune response characterized by a dynamic interplay between the bone marrow (BM) and the ischaemic heart. However, the effect of metabolic alterations such as hypertriglyceridaemia (HTG) on this inter-organ communication remains unknown. In the present study, we have investigated, in a rat model of crossed-BM transplant, the impact of HTG on the BM–heart axis response to AMI under constant metabolic stress. Methods and results: Wistar rats (n = 56) were assigned to two groups: one fed a high-sucrose diet to induce HTG and the other fed a regular chow [normolipemic (NL)-animals]. After 3 weeks, all combinations of crossed-BM transplants were performed (NL-BM/NL-recipient, NL-BM/HTG-recipient, HTG-BM/NL-recipient, and HTG-BM/HTG-recipient) following total body irradiation (9.5 Gy). All animals, except for the NL-BM/NL-recipient group, continued on a high-sucrose diet for 3 weeks. Then, AMI was induced by transient coronary artery ligation, and 5 days later, animals were sacrificed. We determined infarct size and performed echocardiography, 1H-NMR spectroscopy, and multiple molecular and histological analyses. NL-BM/HTG-recipients exhibited smaller infarcts vs. the other groups and showed a resolving inflammatory response, lower lipotoxicity, higher ω3 content, increased AMPK activation and S1P-related enzymes, and reparative fibrosis in the healing scar. Although no differences were detected in left ventricular ejection fraction post-AMI among all groups, NL-BM/HTG-recipients exhibited improved systolic and diastolic parameters. Circulating triglyceride levels were significantly reduced in NL-BM/HTG-recipients 3 weeks post-BM transplant, whereas, conversely, they were found to be enhanced in HTG-BM/NL-recipients developing a HTG state. Furthermore, recipients of a HTG-BM showed a worsened lipid profile, liver steatosis and inflammation, higher weight gain, leptin levels and lower lipoprotein lipase, AMPK, and acetyl-CoA carboxylase activity in the visceral adipose tissue vs. NL-BM-recipient animals. Conclusion: Transplantation of healthy BM into HTG animals enhances the capacity to counteract myocardial injury post-AMI and restores metabolic disturbances, improving overall recovery.


  • Open Access

    CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma

    by Daniel H. Chen, Maeve O'REilly, Kathleen P. Cheok, Ryan Low, Rajesh Puranik, Samuel Clark, John Malcolm Walker, Charlotte Manisty, Arjun K. Ghosh, Claire Roddie

    Introduction: Chimeric antigen receptor T‐cell (CAR‐T) therapy is highly effective in B‐cell blood cancers, but there is limited data on its safety and efficacy in intra‐cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo‐progression.Discussion: We discuss four high‐risk cases that were managed with a multi‐disciplinary approach, including baseline cardiac risk assessment and surveillance with multimodal cardiac imaging and serum cardiac biomarkers, elective supportive care in the intensive care unit, and early treatment of cytokine release syndrome.Conclusion: CAR‐T therapy can be effective and safe in the treatment of B‐cell blood cancers with intra‐cardiac disease.


  • Open Access

    Anthracyclines and Biomarkers of Myocardial Injury

    by Michael Mallouppas, Robin Chung, Arjun K. Ghosh, Alison Macklin, Derek M. Yellon, J. Malcolm Walker


  • Open Access

    Improving cardiovascular magnetic resonance access in low- and middle-income countries for cardiomyopathy assessment: rapid cardiovascular magnetic resonance

    by Katia Devorha Menacho, Sara Ramirez, Aylen Perez, Laura Dragonetti, Diego Perez de Arenaza, Diana Katekaru, Violeta Illatopa, Sara Munive, Bertha Rodriguez, Ana Shimabukuro, et al.

    Aims: To evaluate the impact of a simplified, rapid cardiovascular magnetic resonance (CMR) protocol embedded in care and supported by a partner education programme on the management of cardiomyopathy (CMP) in low- and middle-income countries (LMICs). Methods and results: Rapid CMR focused particularly on CMP was implemented in 11 centres, 7 cities, 5 countries, and 3 continents linked to training courses for local professionals. Patients were followed up for 24 months to assess impact. The rate of subsequent adoption was tracked. Five CMR conferences were delivered (920 attendees—potential referrers, radiographers, reporting cardiologists, or radiologists) and five new centres starting CMR. Six hundred and one patients were scanned. Cardiovascular magnetic resonance indications were 24% non-contrast T2* scans [myocardial iron overload (MIO)] and 72% suspected/known cardiomyopathies (including ischaemic and viability). Ninety-eighty per cent of studies were of diagnostic quality. The average scan time was 22 ± 6 min (contrast) and 12 ± 4 min (non-contrast), a potential cost/throughput reduction of between 30 and 60%. Cardiovascular magnetic resonance findings impacted management in 62%, including a new diagnosis in 22% and MIO detected in 30% of non-contrast scans. Nine centres continued using rapid CMR 2 years later (typically 1–2 days per week, 30 min slots). Conclusions: Rapid CMR of diagnostic quality can be delivered using available technology in LMICs. When embedded in care and a training programme, costs are lower, care is improved, and services can be sustained over time.


  • Open Access

    Use of rapid cardiac magnetic resonance imaging to guide chelation therapy in patients with transfusion-dependent thalassaemia in India: UMIMI study

    by Katia Menacho Medina, Amna Abdel-Gadir, Kartik Ganga, Vineeta Ojha, Surya Pratap, Redha Boubertakh, Louise McGrath, João B Augusto, Alexander Rikowski, Nabila Mughal, et al.

    To explore the impact of incorporating a faster cardiac magnetic resonance (CMR) imaging protocol in a low–middle-income country (LMIC) and using the result to guide chelation in transfusion-dependent patients. A prospective UK–India collaborative cohort study was conducted in two cities in India. Two visits 13 months apart included clinical assessment and chelation therapy recommendations based on rapid CMR results. Participants were recruited by the local patient advocate charity, who organized the patient medical camps. The average scanning time was 11.3 ± 2.5 min at the baseline and 9.8 ± 2.4 min (P < 0.001) at follow-up. The baseline visit was attended by 103 patients (mean age 25 years) and 83% attended the second assessment. At baseline, 29% had a cardiac T2* < 20 ms, which represents significant iron loading, and 12% had left ventricular ejection fraction T2* ≥ 17 ms). At 13 months, more patients were taking intensified dual chelation therapy (43% vs. 55%, P = 0.002). In those with cardiac siderosis (baseline T2* < 20 ms), there was an improvement in T2*—10.9 ± 5.9 to 13.5 ± 8.7 ms, P = 0.005—and fewer were classified as having clinically important cardiac iron loading (T2* < 20 ms, 24% vs. 16%, P < 0.001). This is the first illustration in an LMIC that incorporating CMR results into patient management plans can improve cardiac iron loading. For thalassaemia patients in an LMIC, a simplified CMR protocol linked to therapeutic recommendation via the patient camp model led to enhanced chelation therapy and a reduction in cardiac iron in 1 year.


  • Open Access

    Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology

    by Robin Chung, Sara Tyebally, Daniel Chen, Vikas Kapil, J. Malcolm Walker, Daniel Addison, Roohi Ismail-Khan, Avirup Guha, Arjun K Ghosh

    Cardiotoxicity is the umbrella term for cardiovascular side effects of cancer therapies. The most widely recognized phenotype is left ventricular dysfunction, but cardiotoxicity can manifest as arrhythmogenic, vascular, myocarditic and hypertensive toxicities. Hypertension has long been regarded as one of the most prevalent and modifiable cardiovascular risk factors in the general population, but its relevance during the cancer treatment journey may be underestimated. Hypertensive cardiotoxicity occurs de novo in a substantial proportion of treated cancer patients. The pathology is incompletely characterized—natriuresis and renin angiotensin system interactions play a role particularly in conventional treatments, but in novel therapies endothelial dysfunction and the interaction between the cancer and cardiac kinome are implicated. There exists a treatment paradox in that a significant hypertensive response not only mandates anti-hypertensive treatment, but in fact, in certain cancer treatment scenarios, hypertension is a predictor of cancer treatment efficacy and response. In this comprehensive review of over 80,000 patients, we explored the epidemiology, incidence, and mechanistic pathophysiology of hypertensive cardiotoxicity in adjunct, conventional chemotherapy, and novel cancer treatments. Conventional chemotherapy, adjunct treatments, and novel targeted therapies collectively caused new onset hypertension in 33–68% of treated patients. The incidence of hypertensive cardiotoxicity across twenty common novel therapies for any grade hypertension ranged from 4% (imatinib) to 68% (lenvatinib), and high grade 3 or 4 hypertension in <1% (imatinib) to 42% (lenvatinib). The weighted average effect was all-grade hypertension in 24% and grade 3 or 4 hypertension in 8%.


  • Open Access

    Preventing the Cancer Patient of Today From Becoming the Heart Failure Patient of Tomorrow

    by Derek M. Yellon, John Malcolm Walker, Sapna Arjun


  • Open Access

    Cardio-Oncology – A new subspecialty with collaboration at its heart

    by Arjun K. Ghosh, J. Malcolm Walker


  • Top Cited Papers
    Open Access

    Anthracycline Chemotherapy and Cardiotoxicity

    by John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon

    Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today’s anthracycline-treated cancer patients may become tomorrow’s cardiac patient.


  • Open Access

    Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia

    by Paul Kirk, Mary Sheppard, John-Paul Carpenter, Lisa Anderson, Taigang He, Tim St Pierre, Renzo Galanello, Gualtiero Catani, John Wood, Suthat Fucharoen, et al.